Antibody blockade of the programmed death (PD-1) molecule or its ligand (PD-L1) have revolutionized treatment for various types of cancers including lung cancer, head and neck cancer, melanoma, renal cell carcinoma and lymphoma. This evidence concerns the gene CD274 and lung cancer.